Reinventing Aptamer Science: The Neomer Platform In 2022, NeoVentures Biotechnology revolutionized aptamer science by introducing reproducibility, paving the way for the next generation of aptamers. Using our neomer platform, we reduced the number of random nucleotides while preserving optimal structural diversity. This innovation addressed the… Read More »The Next Generation of Aptamers
One story embedded in One Thousand and One Nights is the story of Aladdin. A poor boy, that one day outsmarts the evil sorcerer and get hold of the magic lamp. Inside the lamp lives the genie, who will grant him all his wishes. Now,… Read More »Why Antibodies Wish They Could be DNA
In the dynamic realm of molecular biology, the quest for enhancing diagnostic tools and therapeutic approaches is an ever-evolving journey. One significant breakthrough in this pursuit is the development of the Neomer library, an innovative platform that allows the utilization of identical sequences across various… Read More »A Revolutionary Approach to Aptamer Characterization
NeoVentures’ Neomer aptamer selection method replaces the traditional SELEX process, offering a closed and reproducible space for aptamer development, ensuring consistency in drug level detection. The inclusion of an in-silico immune tolerance step enhances Neomer aptamers’ specificity and selectivity, making them more precise in detecting… Read More »Revolutionizing Drug Level Detection: Neomer Aptamers
In recent years, the field of therapeutics has witnessed remarkable advancements in the development of novel treatment strategies. Among the emerging approaches, aptamers have emerged as powerful tools with immense potential in various therapeutic applications. Aptamers, short single-stranded nucleic acid or peptide molecules, can specifically… Read More »Unlocking Therapeutic Potential: Aptamers as Tools in Medicine
NeoVentures was formed as an aptamer development company in June of 2002, and founded on a very simple principle. Businesses that create real sustainable value for their clients succeed. This does not always seem to be case as we have all seen biotechnology companies that… Read More »Why has NeoVentures succeeded as an Aptamer development company?
Aptamers are selected from large libraries of random sequences, thus aptamers themselves are not designed but the libraries that they are selected from are. The standard method of aptamer design has been for SELEX selection. This involves a synthetic library with a random region flanked… Read More »Aptamer Libraries – What is Neomers?
Antibody Binding vs. Aptamer Binding The immune system has developed very effective screening methods for eliminating antibodies that bind even weakly to self targets such as serum albumin and IgG. Aptamer selection is done outside the body, on the bench which provides many advantages but implicit… Read More »How We Avoid Self-Recognition with Aptamers
The use of the traditional SELEX method for aptamer development has led to the identification of aptamers that bind to a wide diversity of targets. However, there has been limited success with aptamers in therapeutic and diagnostic applications. A key advantage of aptamer development over… Read More »Announcing The Future of Aptamers: Neomers
This is the first of several blogs we will share on our new Neomer process. The image above can be compared to a dilemma in traditional aptamer selection: are the aptamers that are enriching the product of the selection process (I would vote for the… Read More »How We Overcome Process Bias with Neomers
English 
French 
Spanish